PEB
18/10/2013 12:34
GENERAL
REL: 1234 HRS Pacific Edge Limited
GENERAL: PEB: Cxbladder is Supreme Winner at NZ Innovators Awards
18 October 2013
Cxbladder is Supreme Winner at NZ Innovators Awards
Pacific Edge is the 2013 Supreme Winner of the NZ Innovators Award for
Cxbladder, its novel gene test for the detection and management of bladder
cancer.
The citation for the Supreme Award presented in Auckland last night (17
October 2013) says: "Patient compliance is significantly enhanced with the
easy-to-use, in home or in clinic urine sample system. This detection system
minimises the need to go to a laboratory collection centre or wait to see the
specialist at a time when the cancer can be progressing".
Pacific Edge Chief Executive Officer David Darling says Cxbladder is a quick,
cost effective, non-invasive and highly accurate cancer detection test that
has significant advantages over alternative systems.
"Our focus is on developing systems for the early detection of cancers; early
detection and treatment saves lives. The Supreme Award for Cxbladder is
recognition of the commercialisation of the innovation, science and
technology that has gone into developing this novel biomedical product and
the work of the entire team of scientists, technologists and clinicians who
have been involved in its development, here and overseas."
"Pacific Edge is delighted that Cxbladder has now been launched in the US and
is also available to potential bladder cancer patients in New Zealand and
Australia and soon in Spain, the country with the worlds highest incidence of
bladder cancer."
For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800
ABOUT PACIFIC EDGE
Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
company specialising in the discovery and commercialisation of diagnostic and
prognostic technology for the early detection and monitoring of cancer.
Products in development and in clinical trials are accurate and simple to use
genomic and proteomic tools for the earlier detection, improved
characterisation and better management of gastric, bladder, colorectal
cancers and melanoma. The company has recently completed and released its
first product for the detection of bladder cancer, Cxbladder, and is actively
marketing the product to urologists in New Zealand, Australia and soon to be
Spain and the US.
www.pacificedge.co.nz
ABOUT PACIFIC EDGE DIAGNOSTICS
Pacific Edge takes its exciting cancer detection tests to market through its
wholly owned subsidiaries, Pacific Edge Diagnostics NZ Ltd and Pacific Edge
Diagnostics USA Ltd, and selected commercial partners in Australia and Spain,
Healthscope and Oryzon respectively.
www.pacificedgedx.com
ABOUT Cxbladder
Cxbladder is a proprietary, accurate molecular diagnostic test that enables
the non-invasive detection of bladder cancer from a small volume of urine. It
provides general practitioners and urologists with a quick, cost effective
and accurate measure of the presence of the cancer, and provides urologists
with the opportunity to reduce their reliance on the need for invasive tests
such as cystoscopy. The recently published, Journal of Urology in September
2012, multi-centre international clinical study recruited 485 patients from
Australia and New Zealand.
Results show that Cxbladder out-performed all of the benchmark technologies
in the clinical trial and detected nearly all of the tumours of concern to a
urologist; At a performance of 82% sensitivity and 85% specificity the test
sees 100% of T1, 100% of T2, 100% of T3, 100% of Tis and 100% of upper
urinary tract cancers as well as greater than 95% of high grade tumours.
www.cxbladder.com
End CA:00242570 For:PEB Type:GENERAL Time:2013-10-18 12:34:12
